PE20060124A1 - Tabletas de desintegracion que comprenden licarbazepina - Google Patents

Tabletas de desintegracion que comprenden licarbazepina

Info

Publication number
PE20060124A1
PE20060124A1 PE2005000314A PE2005000314A PE20060124A1 PE 20060124 A1 PE20060124 A1 PE 20060124A1 PE 2005000314 A PE2005000314 A PE 2005000314A PE 2005000314 A PE2005000314 A PE 2005000314A PE 20060124 A1 PE20060124 A1 PE 20060124A1
Authority
PE
Peru
Prior art keywords
licarbazepine
disintegration
tablets including
granules
disintegration tablets
Prior art date
Application number
PE2005000314A
Other languages
English (en)
Inventor
Oskar Kalb
Marie-Christine Wolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406381A external-priority patent/GB0406381D0/en
Priority claimed from GB0406737A external-priority patent/GB0406737D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060124A1 publication Critical patent/PE20060124A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL BAJO LA FORMA DE TABLETA DE DESINTEGRACION CON GRANULOS DE LIBERACION CONTROLADA QUE COMPRENDE: 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ[b,f]AZEPIN-5-CARBOXAMIDA O LICARBAZEPINA, PRESENTES EN UNA CANTIDAD DE 60 A 90 % EN PESO DE LOS GRANULOS, CON UN TAMANO DE PARTICULA ENTRE 150 Y 300 um ; Y UN AGENTE DE RETRASO CONSTITUIDO POR LO MENOS POR UN POLIMERO SELECCIONADO DE POLIMETACRILATOS, ETILCELULOSA, HIDROXIETILCELULOSA, HIDROXIPROPILCELULOSA Y METILCELULOSA; Y UN AGENTE DE DESINTEGRACION COMO ALMIDON DE MAIZ O ALMIDON NATURAL. ESTA COMPOSICION PUEDE SER ADAPTADA PARA SER ADMINISTRADA UNA VEZ AL DIA Y ES UTILIZADA EN EL TRATAMIENTO DE PACIENTES CON TRANSTORNOS AFECTIVOS
PE2005000314A 2004-03-22 2005-03-18 Tabletas de desintegracion que comprenden licarbazepina PE20060124A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406381A GB0406381D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406737A GB0406737D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
PE20060124A1 true PE20060124A1 (es) 2006-03-07

Family

ID=34962439

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000314A PE20060124A1 (es) 2004-03-22 2005-03-18 Tabletas de desintegracion que comprenden licarbazepina

Country Status (16)

Country Link
US (1) US20070190143A1 (es)
EP (1) EP1729737A1 (es)
JP (1) JP2007529563A (es)
AR (1) AR048672A1 (es)
AU (1) AU2005226909B2 (es)
BR (1) BRPI0509014A (es)
CA (1) CA2558307A1 (es)
EC (1) ECSP066872A (es)
IL (1) IL177830A0 (es)
MA (1) MA28526B1 (es)
MX (1) MXPA06010809A (es)
NO (1) NO20064783L (es)
PE (1) PE20060124A1 (es)
RU (1) RU2006137329A (es)
TW (1) TW200534859A (es)
WO (1) WO2005092290A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP2380574A1 (en) * 2005-05-06 2011-10-26 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2012091593A1 (en) * 2010-12-31 2012-07-05 Bial - Portela & Ca., S.A. Granulates comprising eslicarbazepine acetate
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
AU2003240654A1 (en) * 2002-05-31 2003-12-19 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina

Also Published As

Publication number Publication date
EP1729737A1 (en) 2006-12-13
MXPA06010809A (es) 2006-12-15
AU2005226909B2 (en) 2009-05-14
MA28526B1 (fr) 2007-04-03
CA2558307A1 (en) 2005-10-06
JP2007529563A (ja) 2007-10-25
WO2005092290A1 (en) 2005-10-06
TW200534859A (en) 2005-11-01
BRPI0509014A (pt) 2007-08-07
AU2005226909A1 (en) 2005-10-06
US20070190143A1 (en) 2007-08-16
IL177830A0 (en) 2006-12-31
RU2006137329A (ru) 2008-06-20
ECSP066872A (es) 2006-11-24
AR048672A1 (es) 2006-05-17
NO20064783L (no) 2006-12-15

Similar Documents

Publication Publication Date Title
PE20060124A1 (es) Tabletas de desintegracion que comprenden licarbazepina
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
BRPI0414311A (pt) formas de dosagem de liberação controlada
HRP20161380T1 (hr) Farmaceutski sastavi za zamjensku terapiju glukokortikoidima
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
JP2009525985A5 (es)
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
CL2008003827A1 (es) Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
AR062167A1 (es) Sistema de administracion gastrorretentivo
RU2012112552A (ru) Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена
JP2010522137A5 (es)
RU2013106172A (ru) Композиция для снятия усталости, состав и их применение
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
US10479842B2 (en) Treating mucosal lesions with hyaluronan delivered from an adhering troche
EP2540294A4 (en) SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
JP2009506044A5 (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed